Get started
Author

Guillaume Manson

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
2022 · Emmanuel Bachy, Steven Le Gouill, et al. · Nature Medicine · 406
PDF
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
2017 · Charles Herbaux, Jordan Gauthier, et al. · Blood · 217
Biomarkers associated with checkpoint inhibitors
2016 · G. Manson, J. Norwood, et al. · Annals of Oncology · 164
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
2019 · Guillaume Manson, Alexandre Thibault Jacques Maria, et al. · Journal for ImmunoTherapy of Cancer · 107
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
2021 · Reid W. Merryman, Luca Castagna, et al. · Leukemia · 82
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
2022 · Laurent Dercle, Shawn Sun, et al. · Radiology · 61
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
2022 · Gaëlle Drillet, Faustine Lhomme, et al. · Blood Advances · 51
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
2019 · Aiping Chen, Fatima-Zohra Mokrane, et al. · Journal of Nuclear Medicine · 46
PDF
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
2019 · Guillaume Manson, Jean-Baptiste Mear, et al. · European Journal of Cancer · 46
PDF
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
2020 · Fatima-Zohra Mokrane, Aiping Chen, et al. · Radiology · 36
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
2015 · Charles Herbaux, Jordan Gauthier, et al. · Blood · 36
Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
2021 · Marion Panhaleux, Olivier Espitia, et al. · European Journal of Cancer · 35
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases
2020 · Guillaume Aussedat, Alexandra Traverse‐Glehen, et al. · British Journal of Haematology · 33
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
2018 · Guillaume Manson, Charles Herbaux, et al. · Blood · 30
Impact of diagnostic investigations in the management of CAR T-cell–associated neurotoxicity
2024 · Matteo Mauget, Sophie Lemercier, et al. · Blood Advances · 27
PDF
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
2024 · Cédric Rossi, Guillaume Manson, et al. · European Journal of Cancer · 25
PDF
Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma
2023 · E. Marchal, X. Palard-Novello, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 24
PDF
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
2019 · Laurent Dercle, Fatima-Zohra Mokrane, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 24
PDF
Checkpoint blockade after kidney transplantation
2018 · Mathieu Lesouhaitier, Caroline Dudreuilh, et al. · European Journal of Cancer · 22
Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
2020 · Guillaume Manson, Pauline Brice, et al. · Haematologica · 19
Hair Repigmentation With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis
2017 · Guillaume Manson, Aurélien Marabelle, et al. · JAMA Dermatology · 17
Next-generation immunotherapies for lymphoma: one foot in the future
2018 · G. Manson, R. Houot · Annals of Oncology · 13
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
2020 · G. Manson, P. Brice, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 12
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
2023 · Laurent Dercle, Shawn Sun, et al. · Radiology · 11
Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
2022 · Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, et al. · European Radiology · 10
PDF
Works count: 68
Citation count: 1,627
H-index: 19
I10-index: 25
Year
Topic
Type